Navigation Links
The Results From a Clinical Trial Led by the Montreal Heart Institute Demonstrate That Drug Reduces Inflammation in Patients With Serious Cardiovascular Disease
Date:11/10/2008

MONTREAL, Nov. 10 /PRNewswire/ -- Montreal Heart Institute Research Centre Director Dr. Jean-Claude Tardif presented yesterday results from a clinical trial demonstrating that VIA-2291, an investigational drug being developed by VIA Pharmaceuticals, Inc., significantly inhibited production of leukotrienes, proposed mediators of vascular inflammation, in patients with serious heart disease. VIA-2291 was well-tolerated with no serious adverse events attributed to the drug. The study was presented in a Special Session at the American Heart Association 2008 Scientific Sessions in New Orleans, Louisiana.

The study of VIA-2291 was designed to establish optimal dosing and safety data in patients with acute coronary syndromes (ACS), who recently had a heart attack or unstable angina. 191 patients were treated once daily for 12 weeks with one of three dose levels of VIA-2291 or placebo. A sub-study of patients continued for an additional 12 weeks of treatment.

Cardiologists have several therapies that help reduce heart disease risk factors, but none that specifically target inflammation, an underlying cause of atherosclerosis, which leads to major adverse cardiac events (MACE), including heart attack and stroke.

VIA-2291 is designed to be a selective and reversible inhibitor of 5-LO, a key enzyme in the biosynthesis of leukotrienes, that are important mediators of inflammation believed to be involved in the development and progression of atherosclerosis.

"VIA-2291 has the potential to be the first drug to specifically target one cardiovascular inflammatory pathway," said Dr. Jean-Claude Tardif, the VIA-2291 ACS trial's principal investigator, director of the Montreal Heart Institute Research Centre and professor of medicine at the Universite de Montreal. "These data support further clinical development of this drug, including larger outcome trials."

Study Results

The trial demonstrated a statistically significant, dose-depende
'/>"/>

SOURCE Montreal Heart Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Chindex International Inc. Reports Second Quarter FY 2009 Financial Results
2. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance
3. MGT Capital Investments Reports Third Quarter 2008 Financial Results and Provides Update on Recent Developments
4. China Sky One Medical, Inc. Announces Record Third Quarter 2008 Results
5. Ellex Announces Six-Month Results on Retina Regeneration Therapy
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
7. InfoLogix to Report Third Quarter Financial Results on November 10, 2008
8. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
9. China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates
10. Fraxel(R) Laser Systems Shown to Provide Superior Results Compared to Pseudo Fractional Laser Technologies
11. NutraCea Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Falls, New York (PRWEB) September 02, 2014 ... ?” This is the question that millions of people ... among health care providers, patients and their families or ... to misdiagnosis due to its distinct similarities to other ... dermatitis, impetigo, bed bug bites, eczema, varicella and many ...
(Date:9/2/2014)... September 02, 2014 Michigan’s health care ... Care Act and the Healthy Michigan Plan. Throughout these ... remains a trusted funding resource for under-served individuals. Federal ... uninsured or underinsured women between the ages of 50 ... 250 percent of the federal poverty level. ...
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides ... collection of employee internet monitoring products ( http://www.os-monitor.com ). ... up to 10% off, on these useful items. ... than 20 different kinds of high end monitoring programs ... for companies of all sizes. With its high end ...
(Date:9/2/2014)... Barcelona, Spain Tuesday 2 September 2014: A simple ... atrial fibrillation (AF), according to research presented at ESC ... Professor Davy said: "Atrial fibrillation (AF) is the most ... failure risk by three-fold and the risk of stroke ... stroke in 1 of 4 cases. However, AF is ...
(Date:9/2/2014)... California (PRWEB) September 02, 2014 Developers ... have announced a new ProIntro Lesson from Pixel Film ... create easy and fresh-looking titles,” said Christina Austin, CEO ... and armature, ProIntro is a definite game changer.” , ... the ProIntro Lesson from Pixel Film Studios. ProIntro is ...
Breaking Medicine News(10 mins):Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 4Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 2Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 3Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3
... been sent to people traveling to the Indian Ocean. ... bites.// ,93 cases have been reported by ... last year’s average of 6. ,According to the HPA's ... had cases of mosquito-borne virus.,Insect repellents, long trousers and ...
... of the awareness of obesity epidemic afflicting the kids in ... of these actions is not up to the mark. ... Progress in Preventing Childhood Obesity: How Do We Measure Up?, ... ,"The very health of the country hangs in ...
... “crisis” over lack of donors at sperm bank clinics. According to ... stock//, women and couples wanting to have children were facing a ... was 459. Ever since, the number had been decreasing. To make ... kids the right to know the identity of their donor father ...
... start by next week the distribution of a drug to ... ,South Africa is being affected by an extremely virulent ... 52 people in the country. The health officials have now ... early as next week to help fight the disease. The ...
... US is asking for an extensive study for the evaluation ... the use of stents. // ,Stents are widely ... eluting stents are had essentially eliminated short-term restenosis as a ... come under a cloud for possible late-term risks. Reports indicate ...
... In a unique way to curb binge drinking, researchers say parents ... that allowing youngsters // to drink at parties and at home ... ,Professor Mark Bellis, the author of the report said ... in moderation and allowed to drink with them were sensible in ...
Cached Medicine News:Health News:Slow Fight Against Childhood Obesity 2Health News:Slow Fight Against Childhood Obesity 3Health News:Shortage of donors at sperm bank clinics 2Health News:South Africa To Make Available Two New Drugs To Fight The TB Outbreak 2
(Date:9/1/2014)... , Sept. 1, 2014 Reportbuyer.com ... Rigid Transparent Plastics: Global Markets ... INTRODUCTION This chapter ... describing the study goals and objectives, reasons ... methodology, information sources and analyst credentials, and ...
(Date:8/30/2014)... 30, 2014   Royal Philips  (NYSE: PHG, AEX: ... a new ultrasound system designed to enable global hospitals ... patient volumes and cost pressures. Making its debut at ... Barcelona this week, Affiniti provides ... with fewer resources deliver high quality patient care. ...
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... (KOLs) can be the difference between a product,s success ... effectively map and stratify KOL targets – and then ... the type of strong relationships upon which successful KOL ... savvy pharma companies have identified internal inconsistencies in their ...
Breaking Medicine Technology:Rigid Transparent Plastics: Global Markets Outside North America 2Rigid Transparent Plastics: Global Markets Outside North America 3Rigid Transparent Plastics: Global Markets Outside North America 4Rigid Transparent Plastics: Global Markets Outside North America 5Rigid Transparent Plastics: Global Markets Outside North America 6Rigid Transparent Plastics: Global Markets Outside North America 7Rigid Transparent Plastics: Global Markets Outside North America 8Rigid Transparent Plastics: Global Markets Outside North America 9Rigid Transparent Plastics: Global Markets Outside North America 10Rigid Transparent Plastics: Global Markets Outside North America 11Rigid Transparent Plastics: Global Markets Outside North America 12Rigid Transparent Plastics: Global Markets Outside North America 13Rigid Transparent Plastics: Global Markets Outside North America 14Rigid Transparent Plastics: Global Markets Outside North America 15Rigid Transparent Plastics: Global Markets Outside North America 16Rigid Transparent Plastics: Global Markets Outside North America 17Rigid Transparent Plastics: Global Markets Outside North America 18Rigid Transparent Plastics: Global Markets Outside North America 19Rigid Transparent Plastics: Global Markets Outside North America 20Rigid Transparent Plastics: Global Markets Outside North America 21Rigid Transparent Plastics: Global Markets Outside North America 22Rigid Transparent Plastics: Global Markets Outside North America 23Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4Implementing a Strategic Thought Leader Management & Engagement System 2
... of GDIR Agonists Under its ... Partnership ... Inc.,(Nasdaq: ARNA ) announced today that initial clinical study ... being investigated,for the treatment of type 2 diabetes under a ...
... following 4 weeks of, treatment with R7128 1500mg and Pegasys(R) plus Copegus(R) ... tolerability comparable to placebo ... Conference Call Scheduled for 4:00PM ET Today -, PRINCETON, N.J., Jan. ... a 4-week Phase 1,clinical trial to evaluate two oral dose levels of ...
Cached Medicine Technology:Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 2Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 3Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: